161 related articles for article (PubMed ID: 34903191)
1. Triplet versus doublet neoadjuvant chemotherapy regimens for locally advanced gastric cancer: a propensity score matching analysis.
Chen Y; He J; Liu D; Xiao J; Chen X; Tang H; Luo D; Shang C; Lian L; Peng J
BMC Cancer; 2021 Dec; 21(1):1328. PubMed ID: 34903191
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant therapy with immune checkpoint inhibitors in combination with chemotherapy vs . chemotherapy alone in HER2(-) locally advanced gastric cancer: A propensity score-matched cohort study.
Xu G; Liu T; Shen J; Guan Q
Chin Med J (Engl); 2024 Feb; ():. PubMed ID: 38420853
[TBL] [Abstract][Full Text] [Related]
3. Clinical Outcome of Doublet and Triplet Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer.
Kim JS; Kang SH; Moon HS; Sung JK; Jeong HY; Sul JY
Korean J Gastroenterol; 2016 Nov; 68(5):245-252. PubMed ID: 27871160
[TBL] [Abstract][Full Text] [Related]
4. A Retrospective Study of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer.
Wang Y; He K; Zhou Z; Zhong Y; Li G; Lu J
Cancer Manag Res; 2020; 12():8491-8496. PubMed ID: 32982442
[TBL] [Abstract][Full Text] [Related]
5. [Prognostic analysis of neoadjuvant chemotherapy for locally advanced gastric cancer with propensity score matching method].
Peng L; Yang W; Zhang Z; Zhi C; Zhou X; Liu H; Hua Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Oct; 21(10):1148-1153. PubMed ID: 30370514
[TBL] [Abstract][Full Text] [Related]
6. The optimal neoadjuvant chemotherapy regimen for locally advanced gastric and gastroesophageal junction adenocarcinoma: a systematic review and Bayesian network meta-analysis.
Wang T; Li C; Li X; Zhai J; Wang S; Shen L
Eur J Med Res; 2022 Nov; 27(1):239. PubMed ID: 36352476
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy
Li Y; Ma FH; Xue LY; Tian YT
World J Gastroenterol; 2020 Feb; 26(8):818-827. PubMed ID: 32148379
[TBL] [Abstract][Full Text] [Related]
8. Survival Benefit of Neoadjuvant Chemotherapy with S-1 Plus Docetaxel for Locally Advanced Gastric Cancer: A Propensity Score-Matched Analysis.
Kano M; Hayano K; Hayashi H; Hanari N; Gunji H; Toyozumi T; Murakami K; Uesato M; Ota S; Matsubara H
Ann Surg Oncol; 2019 Jun; 26(6):1805-1813. PubMed ID: 30977014
[TBL] [Abstract][Full Text] [Related]
9. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
[No Abstract] [Full Text] [Related]
10. Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis.
Wang Y; Cheng X; Cui YH; Hou J; Ji Y; Sun YH; Shen ZB; Liu FL; Liu TS
BMC Cancer; 2018 Jun; 18(1):702. PubMed ID: 29954358
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Neoadjuvant Chemotherapy Combined with Adjuvant Chemotherapy for Locally Advanced Colon Cancer: A Propensity Score-Matching Analysis.
Zeng W; Liu Y; Wang C; Yang C; Lin S; Li W
Medicina (Kaunas); 2022 Oct; 58(11):. PubMed ID: 36363462
[TBL] [Abstract][Full Text] [Related]
12. A comparison between triplet and doublet chemotherapy in improving the survival of patients with advanced gastric cancer: a systematic review and meta-analysis.
Guo X; Zhao F; Ma X; Shen G; Ren D; Zheng F; Du F; Wang Z; Ahmad R; Yuan X; Zhao J; Zhao J
BMC Cancer; 2019 Nov; 19(1):1125. PubMed ID: 31747911
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy Versus Chemotherapy Plus Chemoradiation as Neoadjuvant Therapy for Resectable Gastric Adenocarcinoma: A Multi-institutional Analysis.
Allen CJ; Pointer DT; Blumenthaler AN; Mehta RJ; Hoffe SE; Minsky BD; Smith GL; Blum M; Mansfield PF; Ikoma N; Das P; Ajani J; Dineen SP; Fleming JB; Badgwell BD; Pimiento JM
Ann Surg; 2021 Oct; 274(4):544-548. PubMed ID: 34132693
[TBL] [Abstract][Full Text] [Related]
14. Assessment of indocyanine green tracer-guided lymphadenectomy in laparoscopic gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: results from a multicenter analysis based on propensity matching.
Huang ZN; Su-Yan ; Qiu WW; Liu CH; Chen QY; Zheng CH; Li P; Wang JB; Lin JX; Lu J; Cao LL; Lin M; Tu RH; Lin JL; Zheng HL; Lin GT; Huang CM
Gastric Cancer; 2021 Nov; 24(6):1355-1364. PubMed ID: 34387763
[TBL] [Abstract][Full Text] [Related]
15. Comparison of short- and long-term outcomes between laparoscopic and open gastrectomy for locally advanced gastric cancer following neoadjuvant chemotherapy: a propensity score matching analysis.
Zhong H; Liu X; Tian Y; Cao S; Li Z; Liu G; Sun Y; Zhang X; Han Z; Meng C; Jia Z; Wang Q; Zhou Y
Surg Endosc; 2023 Aug; 37(8):5902-5915. PubMed ID: 37072637
[TBL] [Abstract][Full Text] [Related]
16. Association of Adjuvant Chemotherapy With Overall Survival Among Patients With Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy.
Lin JX; Tang YH; Lin GJ; Ma YB; Desiderio J; Li P; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Lin M; Tu RH; Zheng CH; Parisi A; Truty MJ; Huang CM
JAMA Netw Open; 2022 Apr; 5(4):e225557. PubMed ID: 35363268
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of preoperative S-1 and docetaxel combination chemotherapy in patients with locally advanced gastric cancer.
Kosaka T; Akiyama H; Miyamoto H; Sato S; Tanaka Y; Sato K; Kunisaki C; Endo I
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1047-1055. PubMed ID: 30911769
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant Chemotherapy
Xu W; Wang L; Yan C; He C; Lu S; Ni Z; Hua Z; Zhu Z; Sah BK; Yang Z; Zheng Y; Feng R; Li C; Yao X; Chen M; Liu W; Yan M; Zhu Z
Front Oncol; 2021; 11():718556. PubMed ID: 34497768
[TBL] [Abstract][Full Text] [Related]
19. Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer.
Petrioli R; Marrelli D; Roviello F; D'Ignazio A; Torre P; Chirra M; Savelli V; Ambrosio MR; Francini G; Calomino N; Farsi M; Vernillo R; Francini E
Surg Oncol; 2020 Mar; 32():2-7. PubMed ID: 31670056
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Docetaxel + Oxaliplatin + S-1 vs Oxalipatin + S-1 as Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Propensity Score Matched Analysis.
Zhang X; Huang H; Wei Z; Zhu Z; Yang D; Fu H; Xu J; Hu Z; Zhang Y; You Q; Huang X; Yan R; Wang W; Cai Q
Cancer Manag Res; 2020; 12():6641-6653. PubMed ID: 32801898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
